The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Open accessAbstract
BACKGROUND & AIMS: Diagnostic criteria for metabolic associated fatty liver disease (MAFLD) have been proposed, but not validated. We aimed to compare the diagnostic accuracy of the MAFLD definition vs the existing NAFLD criteria to identify patients with significant fibrosis and to characterize the impact of mild alcohol intake. METHODS: We enrolled 765 Japanese patients with fatty liver (median age 54 years). MAFLD and NAFLD were diagnosed in 79.6% and 70.7% of patients respectively. Significant fibrosis was defined by FIB-4 index ≥1.3 and liver stiffness ≥6.6 kPa using shear wave elastography. Mild alcohol intake was defined as <20 g/day. Factors associated with significant fibrosis were analysed by logistic regression and decision-tree analyses. RESULTS: Liver stiffness was higher in MAFLD compared to NAFLD (7.7 vs 6.8 kPa, P = .0010). In logistic regression, MAFLD (OR 4.401; 95% CI 2.144-10.629; P < .0001), alcohol intake (OR 1.761; 95% CI 1.081-2.853; P = .0234), and NAFLD (OR 1.721; 95%CI 1.009-2.951; P = .0463) were independently associated with significant fibrosis. By decision-tree analysis, MAFLD, but not NAFLD or alcohol consumption was the initial classifier for significant fibrosis. The sensitivity for detecting significant fibrosis was higher for MAFLD than NAFLD (93.9% vs 73.0%). In patients with MAFLD, even mild alcohol intake was associated with an increase in the prevalence of significant fibrosis (25.0% vs 15.5%; P = .0181). CONCLUSIONS: The MAFLD definition better identifies a group with fatty liver and significant fibrosis evaluated by non-invasive tests. Moreover, in patients with MAFLD, even mild alcohol consumption is associated with worsening of hepatic fibrosis measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metabolic-associated fatty liver disease (MAFLD), is the most common finding in patients with TS.717”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [717]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationSterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 4×
“ALT (U/L) 19 (14-29) 4-122 22 (16-33) 4-188 .”
InfluentialMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Griswold, M. G., Fullman, N., Hawley, C., Arian, N., Zimsen, S. R. M., Tymeson, H. D., Venkateswaran, V., Tapp, A. D., Forouzanfar, M. H., Salama, J. S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31310-2 · Cited by 3,524
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 401
Meaning of non‐overlapping patients between the MAFLD and NAFLD definitions
Chan, W., & Wong, V. W. (2022) · Liver International · doi:10.1111/liv.15142 · Cited by 13
Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction
Gaber, Y., AbdAllah, M., Salama, A., Sayed, M. M., Alem, S. A., & Nafady, S. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1952867 · Cited by 12
Wei, S., Song, J., Xie, Y., Huang, J., & Yang, J. (2023) · JMIR Public Health and Surveillance · doi:10.2196/45050 · Cited by 12
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
Lim, Y., Jeong, S., Hong, M., & Han, H. W. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2406173 · Cited by 13
Li, H., Cao, Z., Li, J., King, L., Zhang, Z., Zhao, Y., Zhang, S., Song, Y., Zhang, Q., Chen, L., et al. (2023) · Nutrients · doi:10.3390/nu15214588 · Cited by 12
Hou, M., Gu, Q., Cui, J., Dou, Y., Huang, X., Li, J., Qiao, L., & Nan, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003141 · Cited by 12
Metabolic-associated steatotic liver disease and hepatocellular carcinoma
Catalano, G., Chatzipanagiotou, O. P., Kawashima, J., & Pawlik, T. M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2426680 · Cited by 13
Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
Singh, S. P., Anirvan, P., Khandelwal, R., & Satapathy, S. K. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00174 · Cited by 12
Rivera‐Íñiguez, I., Panduro, A., Román, S., & González-Aldaco, K. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100874 · Cited by 12
Hu, Y., Zhou, F., Lei, F., Lin, L., Huang, X., Sun, T., Liu, W., Zhang, X., Cai, J., She, Z., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115354 · Cited by 12
Lee, Y., Cho, E. J., Choe, E. K., Kwak, M., Yang, J. I., Oh, S., Yim, J. Y., & Chung, G. E. (2024) · Scientific Reports · doi:10.1038/s41598-024-60152-0 · Cited by 11
Kaewdech, A., & Sripongpun, P. (2024) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.v76i4.267556 · Cited by 11
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction
Ciardullo, S., & Perseghin, G. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.39 · Cited by 14
Marc, L., Mihăescu, A., Lupușoru, R., Grosu, I. D., Gădălean, F., Bob, F. R., Chisavu, L. A., Olariu, N., Tucicovschi, V., Timar, B., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.788881 · Cited by 11
Suzuki, Y., Maekawa, S., Yamashita, K., Osawa, L., Komiyama, Y., Nakakuki, N., Takada, H., Muraoka, M., Sato, M., Takano, S., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16154 · Cited by 12
Liang, D., Zhang, J., Li, L., Li, Y., Xu, L., & Wu, H. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1403720 · Cited by 10
Rodríguez‐Antonio, I., López-Sánchez, G. N., Reyes-Gómez, V. A., Contreras-Flores, E. H., Farías-García, F., Espejel-Deloiza, M., Durán-Padilla, M. A., Chablé-Montero, F., Uribe, M., Chávez-Tapia, N. C., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100651 · Cited by 11
Metabolic-associated fatty liver disease and the role of hormones in its aetiopathogenesis
Suwała, S., & Junik, R. (2024) · Endokrynologia Polska · doi:10.5603/ep.99689 · Cited by 13
Zheng, X., Zhao, D., Wang, L., Wang, Y., Chen, Y., & Zhang, Y. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae553 · Cited by 10
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk
Mostafa, A. M., Pan, Z., Yu, M., Örmecı, N., Fouad, Y. M., & Eslam, M. (2025) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s506402 · Cited by 15
Wang, J., Liu, S., Cao, Q., Wu, S., Niu, J., Zheng, R., Bie, L., Xin, Z., Zhu, Y., Wang, S., et al. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0888-8 · Cited by 10
Sogabe, M., Okahisa, T., Kagawa, M., Ueda, H., Kagemoto, K., Tanaka, H., Kida, Y., Tomonari, T., Taniguchi, T., Okamoto, K., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.03.020 · Cited by 10
Sohouli, M. H., Rohani, P., Hosseinzadeh, M., & Hekmatdoost, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-33407-5 · Cited by 10
Alomari, M., Rashid, M. U., Chadalavada, P. N., Ragheb, J. G., Zafar, H., Suarez, Z. K., Khazaaleh, S., Gonzalez, A. J., & Castro, F. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.477 · Cited by 11
de Groot, J., Santos, S., Geurtsen, M. L., Felix, J. F., & Jaddoe, V. W. V. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102248 · Cited by 10
Translational Control in Liver Disease
Balvey, A., & Fernández, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.795298 · Cited by 10
MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life
Attia, D. I., Aty, N. A., Shawket, A., Said, E., & Fouad, Y. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00485 · Cited by 10
Rui, F., Yang, H., Hu, X., Xue, Q. C., Xu, Y., Shi, J., & Li, J. (2022) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000089 · Cited by 10
MAFLD, patient-centred care, and APASL
Sarin, S. K., Eslam, M., Fan, J., Lin, H., George, J., & Omata, M. (2022) · Hepatology International · doi:10.1007/s12072-022-10408-6 · Cited by 10
Xu, X., Zhou, X., Tian, T., Ding, Y., Yu, C., Zhao, W. G., Wang, X., Lu, J., Guo, W., Jiang, L., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00154 · Cited by 10
Recent advances in NAFLD: current areas of contention
Jennison, E., & Byrne, C. D. (2023) · Faculty Reviews · doi:10.12703/r/12-10 · Cited by 10
Angelico, F., Pastori, D., & Ben, M. D. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.015 · Cited by 10
Choudhury, A. K., Rajaram, R. B., & Sarin, S. K. (2024) · Hepatology International · doi:10.1007/s12072-024-10711-4 · Cited by 10
Chang, H., Liang, S.-X., Li, Z.-Y., Li, R.-N., Zhu, H.-B., He, M., Cui, H., He, J., Li, Y., Wang, J.-R., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06670-5 · Cited by 9
Park, H., Yoon, E. L., Kim, M., Kim, J. H., Cho, S., Jun, D. W., & Nah, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194625 · Cited by 9
Han, E., Chun, H. S., Lee, Y., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Lee, B., Kang, E. S., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16261 · Cited by 9
From NAFLD to MAFLD: Not just a change in the name
Zeng, J., & Fan, J. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.05.007 · Cited by 9
Nakano, M., Kuromatsu, R., & Kawaguchi, T. (2023) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms7012010 · Cited by 8
Shu, S., Li, Y., Yu, X., Chen, X., Abdullah, U., & Yu, Y. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.117776 · Cited by 8
Metabolic dysfunction-associated steatotic liver disease and its associated health risks
Liu, X.-R., Yin, S., Chen, Y.-T., & Lee, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001230 · Cited by 8
Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease
Kido, H., Mizukoshi, E., Yanagi, M., Li, S., Seike, T., Nakagawa, H., Yamashima, T., Shiraishi, Y., Ozaki, N., Harada, K., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02257-5 · Cited by 8
Mino, M., Kakazu, E., Sano, A., Katsuyama, H., Hakoshima, M., Yanai, H., Aoki, Y., Imamura, M., Yamazoe, T., Mori, T., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13898 · Cited by 8
Association between physical activity and diet quality of obese and non-obese MAFLD
Wang, S., Xia, B. X., Luo, T., & Wang, P. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.022 · Cited by 8
Yeoh, A. J., Yang, Z., Cheung, R. C., Do, A., Ahmed, A., & Wong, R. J. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001921 · Cited by 8
Lu, Y., Ge, L., Yang, H. J., He, Y., & Wang, Y. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s402814 · Cited by 8
Cho, Y., Chang, Y., Ryu, S., Wild, S. H., & Byrne, C. D. (2023) · Liver International · doi:10.1111/liv.15661 · Cited by 8
Hou, J., Wu, Q.-W., & Zhang, L. R. (2023) · Journal of Nutritional Science · doi:10.1017/jns.2023.99 · Cited by 8
Kaya, E., Zedginidze, A., Bechmann, L. P., & Canbay, A. E. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-548 · Cited by 8
Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease
Takahashi, A., Ohira, H., Abe, K., Zeniya, M., Abe, M., Arinaga‐Hino, T., Nakamoto, N., Takaki, A., Kang, J., Joshita, S., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3112-23 · Cited by 7
Cheng, Y.-M., Wang, S.-W., Wang, C., & Kao, J. (2024) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_253_23 · Cited by 7
Shi, G.-X., Qian, Y.-S., Jiang, C., Liu, Z., Yang, X., Xu, Y., Jin, S.-S., Chu, J., Qian, G., & Yang, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-76922-9 · Cited by 7
Tajirika, S., Miwa, T., Francisque, C., Hanai, T., Imamura, N., Adachi, M., Horita, R., Menezes, L., Shimizu, M., & Yamamoto, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-34942-x · Cited by 7
Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis
Yang, S., Zhang, R., Deng, W., Chang, S.-C., Li, Y., & Li, S. (2023) · Inflammation Research · doi:10.1007/s00011-023-01776-2 · Cited by 7
Wu, Z., Huang, K., Bao, S., Zhang, X., Li, J., Kong, W., Shi, Y., & Xie, Y. (2024) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2024.2305268 · Cited by 8
Han, A. L., Lee, H. K., & Shin, S. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0276 · Cited by 7
Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
Imai, J., Takashimizu, S., Suzuki, N., Ohshinden, K., Sawamoto, K., Mishima, Y., Tsuruya, K., Arase, Y., Yamano, M., Kishimoto, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-64301-3 · Cited by 7
Lahnsteiner, A., Ellmer, V., Oberlercher, A., Liutkevičiūtė, Z., Schönauer, E., Paulweber, B., Aigner, E. S., & Risch, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-70749-0 · Cited by 8
Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease
Alharthi, J., & Eslam, M. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-269 · Cited by 7
Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
Cao, W., Xu, Y., Shen, Y., Wang, Y., Ma, X., & Bao, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s328206 · Cited by 7
Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
Perdomo, C. M., Núñez-Córdoba, J. M., Ezponda, A., Mendoza, F. J., Ampuero, J., Bastarrika, G., Frühbeck, G., & Escalada, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1023583 · Cited by 7
Kang, M. K., Lee, Y. R., Jang, S. Y., Tak, W. Y., Kweon, Y. O., Song, J. E., Loomba, R. S., Park, S. Y., & Park, J. G. (2023) · Hepatology International · doi:10.1007/s12072-023-10517-w · Cited by 7
Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease
Tsutsumi, T., Kawaguchi, T., Nakano, D., & Torimura, T. (2022) · Hepatology Research · doi:10.1111/hepr.13738 · Cited by 7
Fouad, Y., Elwakil, R., Sanai, F. M., Ojo, O. S., Awadhi, S. A., Ocama, P., Abdelkader, N. A., Al‐Busafi, S. A., Awuku, Y. A., Zaki, S., et al. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102180 · Cited by 7
Yang, C., Tsai, Y., Wang, S., Wu, J., Liu, T., Hsu, W., Huang, P., Chuang, M., Sheu, M., & Lai, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1321155 · Cited by 6
Association of PNPLA3 I148M with Liver Disease Biomarkers in Latinos
Roe, J., García, L. A., Klimentidis, Y. C., & Coletta, D. K. (2021) · Human Heredity · doi:10.1159/000520734 · Cited by 6
Kołakowski, A., Dziemitko, S., Chmielecka, A., Żywno, H., Bzdęga, W., Charytoniuk, T., Chabowski, A., & Konstantynowicz-Nowicka, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911380 · Cited by 6
Vanlerberghe, B. T. K., van Malenstein, H., Sainz‐Barriga, M., Jochmans, I., Cassiman, D. M., Monbaliu, D. R. L., der Merwe, V., Pirenne, J., Nevens, F., & Verbeek, J. (2023) · Clinical Transplantation · doi:10.1111/ctr.14965 · Cited by 6
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD
Yang, Z., Yang, J., Cai, J., Zhang, X., Zhang, P., She, Z., & Li, H. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2406157 · Cited by 6
New criteria for metabolic dysfunction-associated fatty liver disease: advantage or question? Review
Solomentseva, Т. А. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-4-84 · Cited by 6
Pre-MASLD: Should it be defined separately?
Huang, H., Li, Y., & Xu, C. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.10.003 · Cited by 6
Sogabe, M., Okahis, T., Kagawa, M., Sei, M., Ueda, H., Yokoyama, R., Kagemoto, K., Tanaka, H., Kida, Y., Nakamura, F., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103036 · Cited by 7
Sohouli, M. H., Fatahi, S., Magalhães, E. I. D. S., de Oliveira, B. R., Rohani, P., Ezoddin, N., Roshan, M. M., & Hekmatdoost, A. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.934845 · Cited by 6
Uehara, T., Wakui, H., & Tamura, K. (2023) · Hypertension Research · doi:10.1038/s41440-023-01241-x · Cited by 6
Isshiki, A., Fujiwara, K., Kondo, T., Yoshida, K., Yamaguchi, T., & Hirata, S. (2024) · Journal of Medical Ultrasonics · doi:10.1007/s10396-024-01509-w · Cited by 5
Liu, C., Li, C., Fu, J., Bai, L., Wang, M., Song, P., & Zheng, M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04195-1 · Cited by 5
Ono, Y., Sakai, K., Okamura, T., Okada, H., Obora, A., Kojima, T., Hamaguchi, M., & Fukui, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334720 · Cited by 6
Suzuki, K., Tsujiguchi, H., Hara, A., Takeshita, Y., Goto, H., Nakano, Y., Yamamoto, R., Takayama, H., Tajima, A., Yamashita, T., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14351 · Cited by 5
Wei, J., Xu, Z., Li, H., Du, W.-Q., Niu, B.-L., Li, S., Tian, S., Wu, J., Chen, Y., Li, X., et al. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.60780 · Cited by 5
Tamaki, N., Kurosaki, M., Higuchi, M., & Izumi, N. (2021) · Hepatology Research · doi:10.1111/hepr.13700 · Cited by 5
Huang, C., Liang, P., Wang, C., Jang, T., Hsu, P., Tsai, P., Wei, Y., Yeh, M., Hsieh, M., Lin, Y., et al. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12804 · Cited by 5
Nakamura, T., Nakano, M., Tsutsumi, T., Amano, K., & Kawaguchi, T. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0372 · Cited by 5
Sogabe, M., Okahisa, T., Kagawa, M., Kashihara, T., Shinomiya, R., Miyake, T., Kawaguchi, T., Yokoyama, R., Kagemoto, K., Kida, Y., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18280 · Cited by 5
Shao, C., Ye, J., Li, X., Lin, Y., Feng, S., Liao, B., Wang, W., Gong, X., & Zhong, B. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00371 · Cited by 5
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis
Fan, H. X., Liu, Z., Zhang, P., Wu, S. L., Han, X., Huang, Y., Zhu, Y., Chen, X., & Zhang, T. (2023) · Hepatology International · doi:10.1007/s12072-023-10512-1 · Cited by 5
MAFLD: A game changer redefining fatty liver disease for adults and children
Eslam, M., & George, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.004 · Cited by 5
Dashti, F., Bolandparvaz, A., Panji, A., Hojatifar, Z., Alinejad, M., Mehboodi, M., Maleki, M. H., Mirshekari, A., & Nadimi, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-22467-4 · Cited by 4
Liu, Q., Fan, G., Bi, J., Qin, X., Fang, Q., Wu, M., Mei, S., Wan, Z., Lv, Y., Wang, Y., et al. (2024) · Exposure and Health · doi:10.1007/s12403-024-00629-5 · Cited by 4
Amano, K., Sano, T., Ide, T., Nakano, D., Tsutsumi, T., Arinaga‐Hino, T., Kawaguchi, M., Hirai, S., Miyajima, I., Torimura, T., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.3867-24 · Cited by 4
Gao, S., Peng, X., Zhang, S., Yang, J., Guo, S., Li, Y., Ma, R., Hu, Y., Mulatibieke, K., Zhang, X., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-12658-4 · Cited by 4
Time for micro-RNAs in steatotic liver disease: a case–control study
Stoica, V. C., Apostol, D., Diculescu, M. M., Gârdan, I. P., Gârdan, D. A., Mărunțelu, I., & Constantinescu, I. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1349524 · Cited by 4
Virk, G. S., Vajje, J., Virk, N. K., Mannam, R., Rehman, W. U., Ghobriel, N. G., MIAN, I.-U.-D., & Usama, M. (2023) · Cureus · doi:10.7759/cureus.44413 · Cited by 4
Garbuzenko, D. V., & Belov, D. V. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-194-10-22-34 · Cited by 4
Non-alcoholic Fatty Liver Disease
Kim, S. F., & Choi, J. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_36 · Cited by 4
Measuring the impact of the updated Steatotic liver disease nomenclature and definition
Valenti, L. V. C., Aghemo, A., Forner, A., Petta, S., Romeo, S., & Nahon, P. (2023) · Liver International · doi:10.1111/liv.15731 · Cited by 4
Metabolic fatty liver syndromes: where do we stand in 2024?
Chan, W., & George, J. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16507 · Cited by 4
MAFLD: from a disease framework to patient care
Eslam, M., & George, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10685-3 · Cited by 3
Dallio, M., Romeo, M., Nardo, F. D., Napolitano, C., Vaia, P., Basile, C., Coppola, A., Silvestrin, A., Senese, G., Niosi, M., et al. (2025) · Livers · doi:10.3390/livers5040058 · Cited by 4
Sogabe, M., Okahisa, T., Kagawa, M., Sei, M., Kagemoto, K., Tanaka, H., Kida, Y., Nakamura, F., Tomonari, T., Okamoto, K., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16483 · Cited by 3
Rasoulizadeh, Z., Namazi, A., Sohouli, M. H., Rohani, P., Hekmatdoost, A., & Hosseinzadeh, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-60400-3 · Cited by 3
Xu, M., Han, S., Wu, Q., Ma, S., Cai, H., Xue, M., Liu, F., Xiao, X., Chen, X., & Lin, M. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0947 · Cited by 3
Metadata
- Authors
- Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T.
- Affiliations
- Kurume University (JP)
- The University of Sydney (AU)
- Medical Examination Section Medical Examination Part Facilities Public Utility Foundation Saga Prefectural Health Promotion Foundation Saga Japan
- Saga University (JP)
- Corresponding author
- Yamamura, Sakura
- Eslam, Mohammed
- ORCID
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2020-11-30
- Volume
- 40
- Issue
- 12
- Pages
- 3018-3030
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W3089758949
- Cited by
- 401
- References
- 38
- Citations by year
- 2026: 10 · 2025: 33 · 2024: 85 · 2023: 96 · 2022: 84 · 2021: 84 · 2020: 6
- FWCI
- 48.37
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Liver International (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (acceptedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP20fk0210040)
- Research and Development
- Medical Foundation (APP1107178, APP1108422)
- University of Sydney
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- metabolic-associated fatty liver disease, non-alcoholic fatty liver disease, liver fibrosis, diagnostic accuracy, liver stiffness, shear wave elastography, FIB-4, hepatic steatosis, noninvasive fibrosis assessment
- MeSH terms
- Humans, Liver Cirrhosis, Middle Aged, Prevalence, Logistic Models, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
